Evidence map›Paper›PMID 37566057›Full record

ArticleCells2023

TGF

Jenni Fleischauer, Antonella Lucia Bastone, Anton Selich, Philipp John-Neek, Luisa Weisskoeppel, Dirk Schaudien, Axel Schambach, Michael Rothe

Open access · goldAbstract read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jenni FleischauerInstitute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany.
Antonella Lucia BastoneInstitute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany.
Anton SelichInstitute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany.
Philipp John-NeekInstitute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany.
Luisa WeisskoeppelInstitute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany.
Dirk SchaudienDepartment of Inhalation Toxicology, Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Nikolai Fuchs Strasse 1, 30625 Hannover, Germany.
Axel SchambachInstitute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany.
Michael RotheInstitute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany.
Medizinische Hochschule Hannover · DEFraunhofer Institute for Toxicology and Experimental Medicine · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Murine hematopoietic stem and progenitor cells (HSPCs) are commonly used as model systems during gene therapeutic retroviral vector development and preclinical biosafety assessment. Here, we developed cell culture conditions to maintain stemness and prevent differentiation during HSPC culture. We used the small compounds A83-01, pomalidomide, and UM171 (APU). Highly purified LSK SLAM cells expanded in medium containing SCF, IL-3, FLT3-L, and IL-11 but rapidly differentiated to myeloid progenitors and mast cells. The supplementation of APU attenuated the differentiation and preserved the stemness of HSPCs. The TGFβ inhibitor A83-01 was identified as the major effector. It significantly inhibited the mast-cell-associated expression of FcεR1α and the transcription of genes regulating the formation of granules and promoted a 3800-fold expansion of LSK cells. As a functional readout, we used expanded HSPCs in state-of-the-art genotoxicity assays. Like fresh cells, APU-expanded HSPCs transduced with a mutagenic retroviral vector developed a myeloid differentiation block with clonal restriction and dysregulated oncogenic transcriptomic signatures due to vector integration near the high-risk locus

Indexed as

Hematopoietic Stem CellsTransforming Growth Factor betaAnimalsCell ProliferationGenetic TherapyMicePyrazolesThiosemicarbazonesA-83-01PyrazolesThiosemicarbazonesTransforming Growth Factor betaA83-01gene therapygenotoxicityhematopoietic stem and progenitor cellsIVIMmast cellsSAGAstem cell expansionTGFbeta signaling

Identifiers

PMID37566057
PMCPMC10416825
OpenAlexW4385446740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.